Beginning to see the light

Sep 29, 2008
Molecular mechanisms of vision
Molecular mechanisms of vision

(PhysOrg.com) -- Scientists have detailed the active form of a protein which they hope will enhance our understanding of the molecular mechanisms of vision, and advance drug design.

Writing in the journal Nature, the team, including Dr Norbert Krauss from Queen Mary’s School of Biological and Chemical Sciences, has detailed the active structure of a G-protein coupled receptor for the first time.

G-protein coupled receptors are found in the cell membranes of many different animals, and are involved in sensing light and a range of chemical signals including hormones, odours, pheromones and flavours. A huge variety of therapeutic drugs, such as alpha and beta blockers, antihistamines, dopamine agonists and opioids, work by regulating the behaviour of these receptors, and any information about their structure, particularly in an active form, is of valuable use to the pharmaceutical industry.

The team, lead by academics from the Charité (Medical School of Berlin) in Germany and Chonbuk National University in South Korea, studied a G-protein coupled receptor protein called Opsin, which is found in the rod cells of our eyes.

Opsin is the first link in a chain of chemical reactions which allow us to process images and see. First it joins together with another molecule called retinal, forming a protein called Rhodopsin. This in turn reacts with particles of light called photons to join with another protein, the G-protein and stimulate vision.

The team used a technique called X-ray crystallography to analyse the structure of Opsin when it was joined together with the G-protein. They found that Opsin had adopted an active structure, significantly different from its normal inactive state. This explains why Opsin can only bond with the G-protein in its active form, and provides a picture about how Rhodopsin is activated by light, like a mechanical switch.

Dr Krauss explains: “Our findings contribute to our understanding of the primary processes underlying vision. They might also help to model the interactions of other pairs of G-protein coupled receptors and G-proteins. As Rhodopsin/Opsin is now the first example of a G-protein coupled receptor where structures of both the active and inactive forms are known, it might also serve as a model system for selectively designing therapeutic drugs which function as agonists or antagonists of G-protein coupled receptor activity.”

Citation: 'Crystal structure of opsin in its G-protein-interacting conformation' by Patrick Scheerer, Jung Hee Park et al. will be published in the journal Nature on Thursday, 25th September.

Provided by Queen Mary, University of London

Explore further: Researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies

add to favorites email to friend print save as pdf

Related Stories

Chemist develops X-ray vision for quality assurance

29 minutes ago

It is seldom sufficient to read the declaration of contents if you need to know precisely what substances a product contains. In fact, to do this you need to be a highly skilled chemist or to have genuine ...

The future of ultrashort laser pulses

38 minutes ago

Rapid advances in techniques for the creation of ultra-short laser pulses promise to boost our knowledge of electron motions to an unprecedented level.

Recommended for you

Immune response may cause harm in brain injuries, disorders

59 minutes ago

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, ...

One route to malaria drug resistance found

4 hours ago

Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug. The discovery, at Washington University School of Medicine in St. Louis, also is relevant for other infectious ...

Protein therapy successful in treating injured lung cells

5 hours ago

Cardiovascular researchers at The Ohio State University Wexner Medical Center have successfully used a protein known as MG53 to treat acute and chronic lung cell injury. Additionally, application of this protein proved to ...

User comments : 0